Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.89 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.89 |
| ▸ | ITGB6 | P18564 | 10/20 | 0.70 |
| ▸ | ITGB8 | P26012 | 10/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6106306 | 1.00 | ITGAV (0.89) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6111953 | 1.00 | ITGAV (0.89) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6536085 | 0.94 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL7318506 | 0.94 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6106842 | 0.94 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6108645 | 0.94 | ITGAV (0.95) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6107105 | 0.94 | ITGAV (0.95) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6107101 | 0.94 | ITGAV (0.95) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL7437065 | 0.86 | ITGAV (0.84) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL7444216 | 0.86 | ITGAV (0.84) | ITGAVITGB3ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019037-A1 | Alpha V integrin receptor antagonists | ASKEW BEN C (US) | 2004-01-29 | — | — | US | claimed |
| US-20010053853-A1 | Alpha V integrin receptor antagonists | MERCK & CO., INC. | 2001-12-20 | — | — | US | claimed |
| US-7153862-B2 | αv integrin receptor antagonists | MERCK & CO., INC. (US) | 2006-12-26 | — | — | US | disclosed |
| US-6693101-B2 | ALKANOIC ACID DERIVATIVE; INTEGRIN RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2004-02-17 | — | — | US | disclosed |
| US-20040019037-A1 | Alpha V integrin receptor antagonists | ASKEW BEN C (US) | 2004-01-29 | — | — | US | disclosed |
| US-20010053853-A1 | Alpha V integrin receptor antagonists | MERCK & CO., INC. | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019037-A1 | Alpha V integrin receptor antagonists | ITGAV, ADGRE5, ITGA5 | ITGAV 1/4885ITGB3 4/4885ITGB6 19/4885 |
| US-20010053853-A1 | Alpha V integrin receptor antagonists | ITGAV, ADGRE5, ITGA5 | ITGAV 1/4885ITGB3 4/4885ITGB6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.